181 related articles for article (PubMed ID: 20620059)
1. Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitors.
Liu H; Kuhn C; Feru F; Jacques SL; Deshmukh GD; Ye P; Rennie GR; Johnson T; Kazmirski S; Low S; Coli R; Ding YH; Cheng AC; Tecle H; English JM; Stanton R; Wu JC
Bioorg Med Chem Lett; 2010 Aug; 20(16):4885-91. PubMed ID: 20620059
[TBL] [Abstract][Full Text] [Related]
2. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.
Ahn YM; Clare M; Ensinger CL; Hood MM; Lord JW; Lu WP; Miller DF; Patt WC; Smith BD; Vogeti L; Kaufman MD; Petillo PA; Wise SC; Abendroth J; Chun L; Clark R; Feese M; Kim H; Stewart L; Flynn DL
Bioorg Med Chem Lett; 2010 Oct; 20(19):5793-8. PubMed ID: 20800479
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
Getlik M; Grütter C; Simard JR; Nguyen HD; Robubi A; Aust B; van Otterlo WA; Rauh D
Eur J Med Chem; 2012 Feb; 48():1-15. PubMed ID: 22154891
[TBL] [Abstract][Full Text] [Related]
4. 5-amino-pyrazoles as potent and selective p38α inhibitors.
Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
[TBL] [Abstract][Full Text] [Related]
5. Displacement assay for the detection of stabilizers of inactive kinase conformations.
Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
[TBL] [Abstract][Full Text] [Related]
6. Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Xu S; Henkle B; Sherman L; Plant M; Miner K; McBride H; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2009 Aug; 19(16):4724-8. PubMed ID: 19574047
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase.
Sack JS; Kish KF; Pokross M; Xie D; Duke GJ; Tredup JA; Kiefer SE; Newitt JA
Acta Crystallogr D Biol Crystallogr; 2008 Jul; D64(Pt 7):705-10. PubMed ID: 18566506
[TBL] [Abstract][Full Text] [Related]
8. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
[TBL] [Abstract][Full Text] [Related]
9. Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes.
Michelotti EL; Moffett KK; Nguyen D; Kelly MJ; Shetty R; Chai X; Northrop K; Namboodiri V; Campbell B; Flynn GA; Fujimoto T; Hollinger FP; Bukhtiyarova M; Springman EB; Karpusas M
Bioorg Med Chem Lett; 2005 Dec; 15(23):5274-9. PubMed ID: 16169718
[TBL] [Abstract][Full Text] [Related]
10. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.
Bukhtiyarova M; Karpusas M; Northrop K; Namboodiri HV; Springman EB
Biochemistry; 2007 May; 46(19):5687-96. PubMed ID: 17441692
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α.
Swann SL; Merta PJ; Kifle L; Groebe D; Sarris K; Hajduk PJ; Sun C
Bioorg Med Chem Lett; 2010 Oct; 20(19):5787-92. PubMed ID: 20471255
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors.
Bhattacharya SK; Aspnes GE; Bagley SW; Boehm M; Brosius AD; Buckbinder L; Chang JS; Dibrino J; Eng H; Frederick KS; Griffith DA; Griffor MC; Guimarães CR; Guzman-Perez A; Han S; Kalgutkar AS; Klug-McLeod J; Garcia-Irizarry C; Li J; Lippa B; Price DA; Southers JA; Walker DP; Wei L; Xiao J; Zawistoski MP; Zhao X
Bioorg Med Chem Lett; 2012 Dec; 22(24):7523-9. PubMed ID: 23153798
[TBL] [Abstract][Full Text] [Related]
14. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
Goettert M; Schattel V; Koch P; Merfort I; Laufer S
Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268
[TBL] [Abstract][Full Text] [Related]
15. Indolin-2-one p38α inhibitors I: design, profiling and crystallographic binding mode.
Eastwood P; González J; Gómez E; Vidal B; Caturla F; Roca R; Balagué C; Orellana A; Domínguez M
Bioorg Med Chem Lett; 2011 Jul; 21(14):4130-3. PubMed ID: 21696951
[TBL] [Abstract][Full Text] [Related]
16. Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.
Herberich B; Cao GQ; Chakrabarti PP; Falsey JR; Pettus L; Rzasa RM; Reed AB; Reichelt A; Sham K; Thaman M; Wurz RP; Xu S; Zhang D; Hsieh F; Lee MR; Syed R; Li V; Grosfeld D; Plant MH; Henkle B; Sherman L; Middleton S; Wong LM; Tasker AS
J Med Chem; 2008 Oct; 51(20):6271-9. PubMed ID: 18817365
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 5-substituted-N-arylpyridazinones as inhibitors of p38 MAP kinase.
Jerome KD; Hepperle ME; Walker JK; Xing L; Devraj RV; Benson AG; Baldus JE; Selness SR
Bioorg Med Chem Lett; 2010 May; 20(10):3146-9. PubMed ID: 20395140
[TBL] [Abstract][Full Text] [Related]
18. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813
[TBL] [Abstract][Full Text] [Related]
19. Implications for selectivity of 3,4-diarylquinolinones as p38alphaMAP kinase inhibitors.
Peifer C; Urich R; Schattel V; Abadleh M; Röttig M; Kohlbacher O; Laufer S
Bioorg Med Chem Lett; 2008 Feb; 18(4):1431-5. PubMed ID: 18207396
[TBL] [Abstract][Full Text] [Related]
20. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
Suplatov D; Kopylov K; Sharapova Y; Švedas V
J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
